China CJC 1295 DAC 2mg 5mg 10mg 15mg with 3rd lab certificate (Sydney Batch Supply)
- Purity Standard≥99.2% (RP-HPLC)
- Assay FormatLyophilized Solid
- Target MarketSydney / Global CROs
Batch-verified compounds rigorously tested under analytical HPLC and LC-MS spectrometry, ready for expedited transit to New South Wales university corridors and industrial biotechnology consortia.
The Greater Sydney metropolitan region has emerged as the premier southern hemisphere corridor for translational biomedical research, cellular pharmacology, and skeletal-muscle regenerative medicine. With focal points spanning the Camperdown/Camperdown-Ultimo Innovation Precinct, the Westmead Health and Innovation District, and the Randwick Health & Innovation Precinct, research groups are continually probing selective androgen receptor modulation to address conditions such as cachexia, sarcopenia, osteopenia, and severe metabolic wasting syndromes.
Selective Androgen Receptor Modulators—broadly known as SARMs—represent a class of therapeutic and research ligands that bind to the nuclear androgen receptor (AR) with high tissue-selectivity. Unlike 17α-alkylated anabolic-androgenic steroids (AAS), oral SARMs (including non-steroidal pharmacophores like Ostarine/MK-2866, Ligandrol/LGD-4033, Testolone/RAD-140, and Cardarine/GW-501516-family nuclear receptor agonists) demonstrate a dissociative anabolic-to-androgenic ratio. This fundamental pharmacological separation allows researchers to investigate targeted myotrophic stimulation, protein retention, and osteogenic differentiation without provoking typical androgenic virilization in secondary reproductive organs.
“For enterprise investigators, university consortia, and independent laboratory directors across Sydney, obtaining research-grade oral SARMs and companion signaling peptides is not simply a matter of catalog order—it demands uncompromising batch analytical authenticity, total transparency in isomer resolution, verifiable heavy metal screening, and structured chain-of-custody documentation under Australian regulatory guidelines.”
Hebei Miaoou Technology Co., Ltd. (operating since 2010) serves as an authoritative synthesis manufacturer and global exporter, delivering research-grade raw active pharmaceutical ingredients (APIs), oral SARMs solutions, and high-purity lyophilized peptides engineered specifically to satisfy the stringent requirements of New South Wales enterprise buyers.
Translational laboratories cannot risk experimental drift caused by sub-potent materials, toxic synthesis byproducts, or uncharacterized stereoisomers. We align every production run with four rigorous quality pillars.
Every batch undergoes ultra-high-performance Reverse-Phase High-Performance Liquid Chromatography (RP-HPLC) utilizing C18 columns and photodiode array (PDA) detectors. We quantify exact retention times, eliminate unresolved trace peaks, and provide chromatograms with full peak integration data to guarantee absolute baseline stability.
To differentiate active non-steroidal ligands from analog counterfeits or racemic impurities, batches are audited through Liquid Chromatography-Mass Spectrometry (LC-MS) confirming exact m/z molecular weight, complemented by Nuclear Magnetic Resonance (NMR) structural analysis verifying clean spatial resonance patterns.
Crucial for oral SARMs solutions and in-vitro toxicity models: Inductively Coupled Plasma Mass Spectrometry (ICP-MS) guarantees lead (Pb), cadmium (Cd), mercury (Hg), and arsenic (As) remain well below ICH Q3D limits (<0.1 ppm). Residual synthesis solvents (DMF, DCM, acetonitrile) are stripped down to non-detectable traces.
| Analytical Parameter | Standard Commercial Grade | Miaoou Enterprise Specification | Impact on Sydney Laboratory Studies |
|---|---|---|---|
| HPLC Target Purity | 95.0% - 97.5% | ≥ 99.0% - 99.8% | Eliminates off-target receptor interaction & cell culture toxicity |
| Molecular Identity | Basic TLC / Infrared only | High-Res LC-MS + 400MHz 1H-NMR | Unquestioned stereoisomer purity and molecular weight assurance |
| Oral Solution Solubilization | Inconsistent suspension / precipitation | Micro-Filtered Clear Solution (PEG-400 / Ethanol / MCT) | Exact volumetric micro-pipetting without dosage fluctuation |
| Endotoxin Quantification | Not monitored (>2.0 EU/mg) | ≤ 0.05 EU/mg (LAL Kinetic Assay) | Prevents false inflammatory cascades in myoblast assays |
| Batch Documentation | Generic, untraceable sheet | Batch-specific COA with Raw Spectral Data | Satisfies internal auditing at UNSW, USYD, and UTS affiliated labs |
Navigating Australian chemical standards, Therapeutic Goods Administration (TGA) scheduling, and customs compliance protocols for non-clinical research substances.
Within the Australian Commonwealth framework, Selective Androgen Receptor Modulators fall under the Poisons Standard (SUSMP), generally classified under Schedule 4 (Prescription Only Medicine / Research Reagents) or banned for unapproved consumer administration. In New South Wales, the importation, handling, and distribution of raw SARMs materials require strict non-human, non-veterinary research labeling, precise chemical identification (CAS registry matching), and an explicit Laboratory Chemical Reagent designation.
Miaoou maintains dedicated regulatory paperwork for Sydney enterprise consignments. Each commercial invoice, packing declaration, and safety data sheet (SDS conforming to GHS 7 standards) explicitly establishes the active substance as reference analytical standard or raw chemistry intermediate for further laboratory manipulation. This procedural rigor shields university procurement units, bio-analytical facilities, and independent CROs from arbitrary customs delays or confiscations by the Australian Border Force (ABF).
Biochemical compounds such as aqueous or ethanol-stabilized oral SARMs, as well as lyophilized signaling peptides (such as CJC-1295, BPC-157, TB-500, and metabolic GLP-1 analogues), are vulnerable to temperature fluctuations, UV degradation, and excessive transit latency. Our supply chain utilizes prioritized air-express routing directly into Kingsford Smith Airport (SYD) Cargo Gateway.
Shipments destined for Sydney facilities are packed in multi-layered, climate-insulating aluminum barrier pouches with vacuum-sealed desiccants or specialized cold-chain gel containers (maintaining 2–8°C or dry-ice equivalent protection when mandated). With real-time batch waypoint tracking and pre-lodged customs manifests, orders routinely transition from synthetic formulation to Sydney receiving docks in rapid turnaround.
From first-generation bicalutamide derivatives to non-steroidal tissue-selective agonists and dual-acting peptide hybrids: mapping the technological trajectory through 2026 and beyond.
Structural optimization of classical arylpropionamide, hydantoin, and quinolinone pharmacophores to eliminate secondary hepatotoxicity and off-target glucocorticoid binding. Our computational chemistry suites evaluate chiral center purity to ensure zero cross-affinity with progesterone or mineralocorticoid pathways.
Oral SARMs have traditionally presented solubility hurdles due to hydrophobic small-molecule profiles. Miaoou is spearheading research into SEDDS (Self-Emulsifying Drug Delivery Systems) and lipid nano-emulsion vehicle compatibility, yielding crystalline API powders that disperse seamlessly into standard carrier matrices without recrystallization.
Sydney biomedical consortia are increasingly moving toward multi-target signaling assays: pairing selective androgen receptor activation with incretin analogues (Semaglutide, Tirzepatide, Retatrutide) and regenerative peptides (BPC-157, TB-500) to simultaneously measure muscle sparing and visceral adipose thermogenesis.
Understanding regional procurement differences enables international trading partners and institutional buyers to build resilient, compliant sourcing strategies.
Characterized by high volume, aggressive merchant e-commerce, and high reliance on domestic re-packagers. While FDA warnings target finished commercial marketing, primary research labs procure directly from certified active material synthesis hubs to bypass third-tier middlemen markups.
Governed by REACH regulations and strict European Medicines Agency (EMA) precursor surveillance. Enterprise purchasers require formal declarations of substance origin, REACH registration exemptions for R&D, and complete safety dossier compliance.
A quality-first market with low tolerance for sub-specification chemicals. Given Australia's isolated geography, laboratories demand dependable supply lines with guaranteed re-shipping policies, impeccable customs compliance, and verified cold-chain packaging stability.
Explore our full analytical inventory available for institutional procurement, custom vial packaging, and bulk wholesale logistics.
Clear, authoritative guidance covering analytical validation, compliance, reconstitution protocols, and international shipping.
Yes, under the condition that the compounds are imported solely as laboratory research reagents or reference standards for non-human, non-clinical, in-vitro or animal preclinical studies by qualified individuals or institutions. In Australia, SARMs fall under Schedule 4 of the Poisons Standard. We supply complete commercial documentation, GHS-compliant Safety Data Sheets (SDS), and custom packaging labels specifying "For Research Laboratory Use Only" to comply fully with Australian Border Force (ABF) entry protocols.
Every single consignment ships with a certified, batch-traceable Certificate of Analysis (COA). Upon request, we furnish raw analytical HPLC chromatograms displaying retention times and peak areas, high-resolution LC-MS mass spectra confirming identity down to 0.1 Da, and NMR structural validation. For injectable-tier reference peptides, endotoxin quantification via kinetic turbidimetric LAL testing is also documented.
Raw SARMs powders (such as pure RAD-140, LGD-4033, or MK-2866) are micronized crystalline chemical APIs intended for analytical compounding, high-throughput screening, or custom dissolution by experienced chemists. Oral SARMs solutions are pre-formulated liquid preparations where the active compound is homogeneously dissolved in pharmaceutical-grade research solvents (such as PEG-400, DMSO, pharmaceutical ethanol, or MCT oil) enabling immediate, precise volumetric dispensing in micrometer concentrations.
Absolutely. Miaoou operates dynamic synthesis and sterile fill-finish cleanrooms. We accommodate custom vial sizes (2ml, 5ml, 10ml, 30ml amber or clear borosilicate glass), custom lyophilized cake masses (1mg to 500mg per vial), bulk vacuum packaging (100g to 25kg drums for raw powders), and OEM private-label branding with individualized batch identification matching your institutional QA protocol.
Lyophilized peptides possess structural stability at ambient temperatures during standard express airfreight. However, to safeguard against extreme tarmac heat during Australian summer transit, we employ vacuum-sealed isothermal aluminum wrapping with phase-change cold packs. For pre-dissolved or sensitive peptide solutions, dedicated cold-chain air express maintaining constant 2–8°C is available with real-time temperature data-logger monitoring.
We possess an industry-leading successful clearance track record due to compliant harmonized tariff coding (HS Codes), non-restricted research declaration phrasing, and accurate chemical nomenclature. In the rare event an institutional consignment experiences an administrative impound or transit damage, Miaoou provides an unconditional complimentary reshipment guarantee or full credit reimbursement backed by our B2B trade policy.
